

Index

- Abetalipoproteinemia, fatty liver, 10
- ABH antigens, colorectal cancer, 200–201
- Absorption of drugs, 130–133
 - achlorhydria and, 141–142
 - colon and, 131
 - drug properties and, 132
 - food and, 131, 147–148
 - intestinal disease, 142–143
 - lipid solubility and, 132
 - liver disease, 143–145
 - motility disorders, 141
 - small intestine and, 131
 - stomach disease, 141–142
- Aging, effect on pharmacokinetics, 148–151
- AIDS: *see* Sexually transmitted intestinal diseases, HIV infection and
- Albumin
 - and bile acids, 45
 - hypoalbuminemia, 71
- Alcoholism, fatty liver
 - alcoholic fatty liver, 7–8
 - alcoholic foamy fat degeneration, 19
- Aldactazide, ascites, 77
- Amiloride, ascites, 77, 78
- Amino acids
 - aromatic, 92–93
 - branched chain, 92, 101
 - transport of, 217, 218
- Ammonia
 - and brain function, 90–91
 - and hepatic encephalopathy, 91–92
 - homeostatic mechanisms, 90
- Anorectal disorders, 264
 - irritable bowel syndrome, 257, 264
 - loperamide in, 264
 - sexually transmitted
 - Chlamydia trachomatis*, 273–274
 - condylomata acuminata, 274
 - herpes simplex virus, 273
 - Neisseria gonorrhoeae*, 272–273
 - symptoms, 272
 - Treponema pallidum*, 274
- Antibiotics, absorption of, 148
- Antipyrine, indicators of hepatic function, 138
- Arginine vasopressin, and ascites, 74–75
- Aromatic amino acids
 - and brain function, 92–93
 - and hepatic encephalopathy, 93
 - homeostatic mechanisms, 92
- Ascites
 - and cirrhosis, 69
 - complications
 - hepatorenal syndrome, 69, 81–82
 - spontaneous bacterial peritonitis, 69, 79, 80–81
 - death related to, 69
 - health deterioration in, 69
 - management of
 - diuretics, 77, 78
 - medically responsive ascites, 77
 - mild ascites, 77
 - moderate ascites, 78
 - paracentesis, 79

- Ascites (*cont.*)
 management of (*cont.*)
 peritoneovenous shunting, 72–73, 79–80
 resistant ascites, 78
 pathogenesis
 arginine vasopressin, 74–75
 atriatriuretic peptides, 76
 catecholamines, 73–74
 glomerular filtration rate, 71–72
 portal hypertension, 70–71
 renal sympathetic nerve activity, 73
 renin–angiotensin–aldosterone system, 72–73
 urinary prostaglandins, 75
 Atrionatriuretic peptides, and ascites, 76
 Azathioprine, inflammatory bowel disease, 302
- Behavioral symptoms, hepatic encephalopathy, 97
- Benzodiazepine antagonists, hepatic encephalopathy, 102
- Bile acid-induced cholestasis
 clinical importance of, 51–52
 high bile acid concentration, 55–59
 biliary phospholipids and, 56–58
 sulfation and, 58
 lithocholic acid (LCA)-induced cholestasis, 52–55
 LCA-sulfates, 54–55
 mechanisms of, 53–54
 prevention of, 53, 55
- Bile acids
 albumin and, 45
 bile acid flow, 42–43
 bicarbonate transport system, 48–49
 bile acid-dependent flow (BADF), 43
 bile acid-independent flow (BAIF), 43, 44, 48, 49
 biliary tree permeability and, 49
 cytoskeletal proteins in, 49
 Na⁺,K⁺-ATPase activity and, 48
 paracellular pathway in, 49–50
 binding of, 46–47
 cellular transport, 46–47
 hepatocyte uptake, 44–45
 lobular uptake, 43–44
 osmotic activity, 42
 portal bile ductular channels and, 50–51
 reabsorption, 42, 50–51
 secretion, 42
 biliary phospholipids, 47, 56–58
- Bile acids (*cont.*)
 secretion (*cont.*)
 canalicular secretion, 47–48
 carrier transport, 47
 cholehepatic pathway and, 51
 fluid phase endocytosis and, 50
 purpose of, 42
 types of, 44, 46, 51–52
- Bile formation, normal bile, components, 41
- Biliary tree, following proximal gastric vagotomy, 186
- Bioavailability of drugs: *see* Pharmacokinetics in gastroenterology
- Biopsy
 celiac disease, 237
 fatty liver, 4
- Brain function
 ammonia and, 90–91
 aromatic amino acids and, 9–93
 necessary elements in, 89
- Branched chain amino acids, hepatic encephalopathy, 101
- Breastfeeding, and celiac disease, 231
- Calcium, role of, gastrointestinal motility, 256–257
- Campylobacter, 275
- Carbohydrates
 carbohydrate antigens, 200
 carbohydrate changes, 199
 colorectal cancer and, carbohydrate-containing marker, 198–199
- Carcinoembryonic antigen, colorectal cancer, markers for, 198
- Catecholamines, and ascites, 73–74
- Celiac disease
 complications
 malignancy, 238–239
 ulcerative ileojejunitis, 239
 unclassified sprue, 239
 diagnosis, 236–237
 noninvasive screening, 237–238
 small intestinal biopsy, 237
 diseases associated with, 236, 238
 environmental influences, 231–232
 adenovirus related findings, 231–232
 breastfeeding, 231
 epidemiology, 229–230
 genetic influences
 families/twin studies, 231, 235

- Celiac disease (*cont.*)
 genetic influences (*cont.*)
 Gm markers, 231
 HLA/non-HLA markers, 230–231
 grain protein activation of, 227–229
 activating/nonactivating cereals, 228, 240
 gliadin fractions and, 228–229
 immunity
 antigliadin antibody, 233
 cell-mediated immunity, 233–234
 humoral immunity, 232–233
 pathogenesis, 234–235
 pathology, 235–236
 intestinal mucosa in, 235
 transient gluten intolerance, 238
 treatment, 239–241
 and failure to respond, 241
 gluten-free diet, 239
 low-gluten diet, 240
 vitamin supplementation, 240
Chlamydia trachomatis, 273–274
 Choleric potential, 58
 Cholestasis, *see also* Bile acid-induced cholestasis
 defined, 41
 mechanisms of, 51
 Cimetidine, drug interactions, 147
 Cirrhosis, *see also* Ascites
 complications of, 69, 80–82
 and fatty liver, 3, 7, 8, 9, 12, 13
 Cisapride, and gastrointestinal motility, 179
 Clearance technique, indicators of hepatic function, 138–139
 Codeine phosphate, diarrhea, 259
 Colon, diarrhea as colonic salvage failure, 262–263
 Colorectal cancer
 blood group antigen changes
 ABH antigens, 200–201
 gastrointestinal cancer-associated antigen, 201–202
 LE^a and LE^b-related antigens, 203–205
 T antigen, 202–203
 carbohydrate antigens, 200
 carbohydrate changes in, 199
 fecal occult blood screening, 198
 high risk subjects, 197
 incidence of, 197
 markers for, 198–199
 carbohydrate-containing molecules, 198–199
 Colorectal cancer (*cont.*)
 markers for (*cont.*)
 carcinoembryonic antigen, 198
 primary prevention, 197
 questions/issues related to, 206
 secondary prevention, 198
 survival rate, 197
 Condylomata acuminata, 274
 Corticosteroids, inflammatory bowel disease, 302
 Craniocerebral trauma, fatty liver, 18
 Crohn's disease, and drug absorption, 142–143; *see also* Inflammatory bowel diseases
 Cryptogenic fatty liver, 21
 CT scan
 fatty liver, 3–4, 16, 20, 21
 islet cell tumors, 120–121
 monoenergetic CT, 3
 spin-echo technique, 3
 Dadron mesocaval shunt, 31
 Delta virus hepatitis, fatty liver, 19
 Devascularization procedures
 extensive devascularization, 35–36
 portal hypertension, 33–36
 esophageal transection, 34
 gastric transection, 34
 transesophageal varix ligation, 33–34
 splenectomy, 34–35
 Sugiura operation, 35
 Diabetes mellitus, fatty liver, 8–9
 Diarrhea
 anorectal disorders, 264
 irritable bowel syndrome, 257, 264
 loperamide in, 264
 antidiarrheal agents
 mechanisms of action, 259
 most effective agents, 261–262
 safe use of, 264, 265
 as colonic salvage failure, 262–263
 definition of, 251
 enteric reflexes, 259–262
 migrating action potential complex, 260–261
 opiates, effect of, 259, 261–262
 sympathomimetic agents, effect of, 262
 toxic substances and, 259–260
 transepithelial potential differences, 261
 excessive fluid ingestion in, 252

- Diarrhea (*cont.*)
- excessive fluid secretion in
 - biomedical factors, 253–254
 - causes of, 252
 - mechanisms of, 252–254
 - gastrointestinal motility, 256–259
 - calcium, role of, 256–257
 - contact time reduction, 257–259
 - decreased activity, 257
 - glucose/electrolyte solutions, use of, 256
 - intestinal absorption, impairment of, 254, 256
 - measure of stool per day and, 251
 - ulcerative colitis, 264–265
- Disseminated intravenous coagulation (DIC)-like syndrome, 80
- Diuretics, ascites, 77, 78
- Domperidone, and gastrointestinal motility, 179
- Dopaminergic drugs
 - dopamine, and gastrointestinal motility, 179
 - hepatic encephalopathy, 101
- Drug interactions, 145–147
 - and gastrointestinal absorption, 146–147
 - and hepatic metabolism, 147
 - mechanisms of, 145
- Drug reactions, fatty liver, 11–12, 18
- Dyspepsia: *see* Gastrointestinal motility
- Edema, and cirrhosis, 69; *see also* Ascites
- EEG, diagnosis, hepatic encephalopathy, 98–99
- Elderly, effect on pharmacokinetics, 148–151
- End-to-side portacaval shunt, 28–29
 - as emergency measure, 29
 - prophylactic/therapeutic trials, 29
- Entamoeba histolytica*, 275–276
- Esophageal transection, 34
- Esophagus
 - abnormalities in GVHD, 167–168
 - following proximal gastric vagotomy, 186
- Ethacrynic acid, ascites, 78
- Extensive devascularization, 35–36
- False neurotransmitter hypothesis, hepatic encephalopathy, 93
- Fatty liver, 1–21
 - causes, 1
- Fatty liver (*cont.*)
 - cirrhosis and 3, 7, 8, 9, 12, 13
 - defined, 1
 - diagnosis, 1
 - biopsy, 4
 - CT scan, 3–4, 16, 20, 21
 - ultrasound, 2–3
 - macrovesicular fat diseases
 - abetalipoproteinemia and, 10
 - alcohol fatty liver, 7–8
 - diabetes mellitus and, 8–9
 - drug related, 11–12
 - hepatitis and, 13
 - histopathology, 4–6
 - jejuno-ileal bypass and, 9
 - kwashiorkor and, 10
 - metabolic liver diseases and, 13
 - obesity related, 8, 9
 - pancreatic disease and, 13
 - parenteral nutrition and, 10
 - ulcerative colitis and, 12
 - wasting diseases and, 12
 - Weber–Christian disease and, 12
 - Wilson’s disease and, 13
 - mechanisms related to, 1–2
 - microvesicular fat diseases
 - alcoholic foamy fat degeneration, 19
 - craniocerebral trauma and, 18
 - cryptogenic fatty liver, 21
 - delta virus hepatitis and, 19
 - focal fatty liver, 19–21
 - histopathology, 13–14
 - mechanisms related to, 14–15
 - pregnancy related, 16
 - Reye’s syndrome and, 17–18
 - sodium valproate toxicity and, 18
 - symptoms of, 15
 - tetracycline toxicity and, 18
 - urea cycle enzyme defects and, 18
 - steatohepatitis and, 3–4, 8, 9
 - symptoms 6
- Fecal fat excretion, following proximal gastric vagotomy, 186
- Fecal occult blood screening, colorectal cancer, 198
- First-pass metabolism and drugs
 - bioavailability, 139–140
 - presystemic metabolism, 133
- Focal fatty liver, 19–21
- Furosemide, ascites, 78

- GABA
 and brain function, 95–96
 and hepatic encephalopathy, 95–97
 homeostatic mechanisms, 94–95
 levels in liver failure, 94
- Gas: *see* Intestinal gas
- Gastric acid secretion, following proximal gastric vagotomy, 184–185
- Gastric transection, 34
- Gastrinomas, islet cell tumors
 omeprazole, 112
 SMS 201-995 treatment, 116–117
- Gastrointestinal cancer-associated antigen, colorectal cancer, 201–202
- Gastrointestinal motility
 abnormal emptying, 177–180
 drug treatments, 178–179
 electromechanical devices in, 179–180
 stress in, 180
 study of, 180
- diarrhea, 256–259
 calcium, role of, 256–257
 contact time reduction, 257–259
 decreased activity, 257
 fed pattern, 176–177
 interdigestive motor complex (IDMC), 175–177
 neural mechanisms, 176
 phases of, 176–177
 and proximal gastric vagotomy, 186
- Genetic factors, celiac disease, 230–231, 235
- Giardia lamblia*, 276
- Glomerular filtration rate, and ascites, 71–72
- Glucagonomas, islet cell tumors, SMS 201–995 treatment, 115
- Glucose/electrolyte solutions, use of, diarrhea, 256
- Glucose intolerance, and fatty liver hepatitis, 9
- Glucose transport, 214–215, 216, 218
- Gluten: *see* Celiac disease
- Glycoproteins and glycolipids, membrane-associated, 198–199
- Graft-versus-host disease (GVHD)
 acute, 159, 163–166
 intestinal GVHD, 163–165
 liver GVHD, 165–166
 chronic, 159, 166–169
 esophageal abnormalities, 167–168
 intestinal changes, 168–169
 liver GVHD, 168
- Graft-versus-host disease (*cont.*)
 grading system, 163
 mortality rates, 163
 symptoms of, 163
- Grains: *see* Celiac disease
- GRFomas, islet cell tumors, SMS 201–995 treatment, 117–118
- Growth hormone releasing factor: *see* GRFomas
- Head-out water immersion, procedure in, 72
- Hepatic encephalopathy
 diagnosis
 clinical features, 97–98
 differential diagnosis, 100
 laboratory tests, 98–99
 disorders similar to, 100
 lack of information about, 89
 pathogenesis
 ammonia hypothesis, 90–92
 false neurotransmitter hypothesis, 92–93
 GABA hypothesis, 93–97
 precipitating factors, 100
 treatment of, 100–102
- Hepatic steatosis: *see* Fatty liver
- Hepatitis, 278
 delta virus hepatitis, 19
 fatty liver, 13
- Hepatorenal syndrome, complications of ascites, 69, 81–82
- Herpes simplex virus, 273
- Hormonal mediation, nutrient transport, 218, 219
- Hydrochlorothiazide, ascites, 77
- Hyperkalemia, 77
- Hyponatremia, 74, 100
- Immunity related disorders: *see* Celiac disease; Inflammatory bowel disease
- Inflammatory bowel disease, immunity and autoimmunity, 293–296
 mucosal effector cell function, 297–302
 B-cell function, 298–299
 cytotoxic cells, 299–301
 macrophages, 301
 mast cells, 301
 polymorphonuclear leukocytes, 301
 treatment, 302–303
 drugs used, 302–303
 triggers for disease, 292–293

- Innocent bystander phenomenon, 165, 166
- Inokuchi shunt, 31–32
- Insulinomas, islet cell tumors, SMS 201–995
treatment, 115–116
- Interdigestive motor complex (IDMC), gas-
trointestinal motility, 175–177
- Interposition mesocaval shunt, 30–31
- Intestinal disease, and drug absorption, 142–
143
- Intestinal function, *see also* Nutrient transport
absorption studies, 210
and growth, 219–220
- Intestinal gas
bicarbonate as liberator, 281
bloating/distension, 286–287
causes of, 286
treatment of, 287
clinical gas syndrome, 285
colonic bacteria and, 282–283
diffusion of, 283
excessive eructation and, 285–286
flatus rate, 283
production/consumption in intestinal tract,
281–282
routes of entry, 279–281
swallowed air, 279–281, 284, 285
treatment approaches, 287–288
dietary regulation, 287–288
types of gases produced, 281, 282, 284, 285
- Intestinal GVHD
acute, 163–165
chronic, intestinal manifestations, 168–169
- Iron transport, 216–217
- Islet cell tumors
classification of, 109–110
incidence of, 109
localization of tumor, 120–122
procedures in, 120–121
treatment of localized tumors, 122
metastatic tumor, 122–124
interferon, 124
SMS 201-995, 123–124
peptides released by, 110
symptom control
of gastrinomas, 116–117
of glucagonomas, 115
of GRFomas, 117–118
of insulinomas, 115–116
omeprazole, 111–112
receptor-blockers, 110
- Islet cell tumors (*cont.*)
symptom control (*cont.*)
SMS 201-995, 113–119
of VIPomas, 113–114
- Jejuno-ileal bypass, fatty liver, 9
- Kwashiorkor, fatty liver, 10
- Lactitol, hepatic encephalopathy, 101
- Lactulose
hepatic encephalopathy, 100
and small intestine transit time, 258
- LE⁺ and LE⁻-related antigens, colorectal can-
cer, 203–205
- Le Vein shunt, 80
- Lidamide, and gastrointestinal motility, 179
- Lithocholic acid (LCA)-induced cholestasis:
see Bile acid-induced cholestasis
- Liver
acute GVHD, 165–166
chronic GVHD, 168
drug clearance, 135–138
calculation of, 136, 137–138
determinants of, 136
extraction ratios, 136, 137, 143–144
liver disease and, 143–145
- Liver function, drug indicators, 138–139
antipyrine, 138
choosing drug for, 138
clearance technique, 138–139
- Liver transplantation, 82
- Loop diuretic, furosemide, 78
- Loperamide, diarrhea, 259, 264
- Lymphatic congestion, 71
- Macrovesicular fat diseases: *see* Fatty liver
- Magnesium sulfate, and small intestine transit
time, 258
- Mannitol, and small intestine transit time, 258
- Markers, of colorectal cancer, 198–199
- Marrow transplants, *see also* Graft-versus-host
disease (GVHD)
histocompatibility, 160
liver/intestinal diseases, causes of, 162
marrow reconstitution, 162
posttransplant immunoprophylaxis, 162
pretransplant conditioning therapy, 160
- Maximal acid output, following proximal gas-
tric vagotomy, 185

- Mesocaval shunt
 Dadron mesocaval shunt, 31
 interposition mesocaval shunt, 30–31
- Metoclopramide, and gastrointestinal motility, 179
- Metronidazole, hepatic encephalopathy, 101
- Microvesicular fat diseases: *see* Fatty liver
- Migrating action potential complex, diarrhea, 260–261
- Moduret, ascites, 77
- Monoenergetic CT, 3
- Motilin, and gastrointestinal motility, 176, 178, 179
- Motility disorders, and drug absorption, 141
- Naloxone, and gastrointestinal motility, 179
- Neisseria gonorrhoeae*, 272–273
- Neomycin, hepatic encephalopathy, 100
- Neurotransmitters, false neurotransmitter hypothesis, 92–93
- NSAID drugs, 75
- Number connection tests, diagnosis, hepatic encephalopathy, 98
- Nutrient transport
 everted sleeve experiments, 211–212
 intestinal brush border transporters
 amino acid transport, 217, 218
 glucose transport, 214–215, 216, 218
 hormonal mediation, 218, 219
 iron transport, 216–217
 nonspecific regulation, 219
 ontogenetic development of, 219–223
 proline transport, 213–214, 218
 regulation of, 213–217
 regulatory signaling, 217–218
 repression of, 215–216, 217
 types of, 212
 vitamin transport, 217
 in pregnancy, 218–219
 in starvation, 219
 transepithelial transport measures, 211
- Omeprazole, symptom control, islet cell tumors, 111–112
- Opiates, effects of diarrhea, 259, 261–262
- Pancreas
 following proximal gastric vagotomy, 186
 pancreatic disease, fatty liver, 13
 pancreatitis, chronic, 256
- Paracentesis, ascites, 79
- Parenteral nutrition, fatty liver, 10
- Peptides, and gastrointestinal motility, 179
- Peritoneovenous shunting
 ascites, 72–73, 79–80
 complications, 79–80
- Peritonitis, spontaneous bacterial peritonitis, ascitic fluid, 80–81
- Pharmacokinetics in gastroenterology
 aging, effects of, 148–150
 bioavailability, 139–140
 absolute availability, 140
 defined, 139
 determination of, 140
 first-pass metabolism and, 139–140
 systemic availability, 140
- disease effects
 intestinal disease, 142–143
 liver disease, 143–145
 motility disorders, 142
 stomach disease, 141–142
- dosage, design of, 130
- drug-drug interaction, 145–147
 and gastrointestinal absorption, 146–147
 and hepatic metabolism, 147
 mechanisms of, 145
- empirical approach, 130
- gastrointestinal absorption, 130–133
 determinants of, 131–133
 food and, 131, 147–148
 half-life, 137
- hepatic drug clearance, 135–138
 calculation of, 136, 137–138
 determinants of, 136
- indicators of hepatic function, 138–139
 antipyrine, 138
 choosing drug for, 138
 clearance technique, 138–139
- nature of, 129–130
- presystemic metabolism, 133–135
 first-pass metabolism, 133
 intestinal drug metabolism, 134–135
- processes in
 absorption, 130
 distribution, 130
 elimination, 130
- Polyethylene glycol, and diarrhea, 259
- Polyps
 adenomatous, 201
 hyperplastic, 201

- Portal hypertension
 and ascites, 70–71
 cirrhosis and, 26
 devascularization procedure, 33–36
 esophageal transection, 34
 extensive devascularization, 33–36
 gastric transection, 34
 Sugiura operation, 35–36
 splenectomy, 34–35
 transesophageal varix ligation, 33–34
 pathophysiology, 25–26
 patient considerations, 26–27
 shunting
 Dadron mesocaval shunt, 31
 end-to-side portacaval shunt, 28–29
 Inokuchi shunt, 31–32
 interposition mesocaval shunt, 30–31
 proximal splenorenal shunt, 30
 side-to-side portasystemic shunts, 30–31
 Warren shunt, 31–33
 surgical decisions
 elective surgery, 37
 emergency surgery, 36
 prophylactic surgery, 36
 treatment considerations, 27–28
 Portasystemic encephalopathy, 69
 Pregnancy, nutrient transport, 218–219
 Proctitis: *see* Anorectal disorders, sexually transmitted
 Proline transport, 213–214, 218
 Propranolol, drug interactions, 147
 Protein–carbohydrate imbalance, fatty liver, 10
 Protozoa, 276
 Proximal gastric vagotomy
 effects of
 biliary tree effects, 186
 esophageal motility, 186
 fecal fat excretion, 186
 gastric motility, 186
 pancreas, 186
 reduced acid secretion, 184–185
 serum gastrin concentration elevation, 185
 indications for, 187–188
 duodenal ulcers, 187, 188
 gastric ulcers, 187–188
 stenosis, 187
 results of
 morbidity, 188
 mortality, 188
 recurrence of ulcers, 189–190
 Proximal gastric vagotomy (*cont.*)
 surgical technique, importance of, 189
 technical aspects, 184
 terms related to, 186
 Proximal splenorenal shunt, 30
 Pseudoperfusion, 30
 Renal sympathetic nerve activity, and ascites, 73
 Renin–angiotensin–aldosterone system, and ascites, 72–73
 Reye's syndrome, fatty liver, 17–18
 Serum gastrin concentration, following proximal gastric vagotomy, 185–186
 Sexually transmitted intestinal diseases
 anorectal infection
 Chlamydia trachomatis, 273–274
 condylomata acuminata, 274
 herpes simplex virus, 273
 Neisseria gonorrhoeae, 272–273
 symptoms, 272
 Treponema pallidum, 274
 Spirochetosis, 276–277
 Entamoeba histolytica, 275–276
 enteric infection
 giardia lamblia, 276
 symptoms, 276
 hepatitis, 278
 HIV infection and, 271
 proctocolitis
 Campylobacter, 275
 Entamoeba histolytica, 275–276
 protozoa, 276
 Shigella, 275
 symptoms, 274–275
 protozoa, 276
 risk factors, 272
 Shigella, 275
 Shunting
 ascites, 72–73, 79–80
 portal hypertension
 end-to-side portacaval shunt, 28–29
 Inokuchi shunt, 31–32
 side-to-side portasystemic shunts, 30–31
 Warren shunt, 31–33
 Side-to-side portasystemic shunts, 30–31
 6-mercaptopurine, inflammatory bowel disease, 302–303

- SMS 201-995 treatment and islet cell tumors
 gastrinomas, 116–117
 glucagonomas, 115
 GRFomas, 117–118
 insulinomas, 115–116
 issues related to, 119
 side effects, 118
 tumor control, 123–124
 VIPomas, 113–114
- Sodium benzoate, hepatic encephalopathy, 101
- Sodium phenylacetate, hepatic encephalopathy, 101
- Sodium retention: *see* Ascites
- Sodium valproate toxicity, fatty liver, 18
- Sorbitol, hepatic encephalopathy, 101
- Spin-echo technique, CT scan, 3
- Spirochetosis, 276–277
- Spirolactone, ascites 77, 78
- Splenectomy, 34–35
- Spontaneous bacterial peritonitis, complications of ascites, 69, 79, 80–81
- Sprue, and celiac disease, 239
- Starling forces, 70
- Starvation, nutrient transport, 219
- Steatohepatitis, and fatty liver, 3–4, 8, 9
- Stomach disease, and drug absorption, 141–142
- Stress
 and diarrhea, 257
 and gastrointestinal motility, 180
- Sugiura operation, 36
- Sulfasalazine, inflammatory bowel disease, 302
- Sulfation, and LCA-induced cholestasis, 58
- Sympathomimetic agents, effect of, diarrhea, 262
- T antigen, colorectal cancer, 202–203
- Taurine supplementation, and LCA-induced cholestasis, 55
- Treponema pallidum*, 274
- Tetracycline toxicity, fatty liver, 18
- Transepithelial potential differences, diarrhea, 261
- Transesophageal varix ligation, 33–34
- Transient gluten intolerance, celiac disease, 238
- Transport maximum, 56
- Triglycerides, fatty liver, 1–2, 8
- Tumors: *see* Islet cell tumors
- Ulcerative colitis, fatty liver, 12; *see also* Inflammatory bowel diseases
- Ulcerative ileojejunitis, celiac disease, 239
- Ulcers: *see* Proximal gastric vagotomy
- Ultrasound, fatty liver, 2–3
- Underfilling theory, portal hypertension, 70
- Urea cycle enzyme defects, fatty liver, 18
- Urinary prostaglandins, and ascites, 75
- Vagotomy: *see* Proximal gastric vagotomy
- Vasopressin, and gastrointestinal motility, 179
- VIPomas, islet cell tumors, SMS 201-995 treatment, 113–114
- Visual evoked response, diagnosis, hepatic encephalopathy, 99
- Vitamin transport, 217
- Warren procedure
 complications of, 32–33
 Warren shunt, 31–33
- Wasting diseases, fatty liver, 12
- Water load test
 excretors/nonexcretors, 75
 lack of free water, 77
- Weber–Christian disease, fatty liver, 12
- Wilson’s disease, fatty liver, 13
- Zaroxynen, ascites, 78
- Zinc, hepatic encephalopathy, 101
- Zollinger–Ellison syndrome, 110, 111, 116, 120, 122
 diarrhea in, 252